Slide 1: ASX Announcement: Investor Presentation
ASX ANNOUNCEMENT INVESTOR PRESENTATION MELBOURNE (AUSTRALIA) 22 April 2026: Invion Limited (ASX: IVX) (“Invion” or the “Company”) will be participating in several upcoming local and international conferences, including BIONNOVA 2026 in Shanghai and Bio Korea 2026. Attached is the presentation that I
Slide 2: New Frontier in Affordable Precision Medicine - BIONNOVA 2026
ASX: IVX For personal use only New Frontier in Affordable Precision Medicine Targeted Cancer Treatment Powered by Light BIONNOVA 2026
Slide 3: Disclaimer
DISCLAIMER For personal use only The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Invion Limited (Company). In p
Slide 4: Need for More Affordable New Treatments
CREATING IMPACT FOR TREATING CANCERS GLOBALLY NEED FOR MORE AFFORDABLE NEW TREATMENTS Commercial Rationale for Photosoft For personal use only Median price of new FDA drugs in 2024 >US$370K1, more than double vs 2021 Works across multiple cancers without need to personalise – precision with less com
Slide 5: Asian-Centric Cancers, a US$40B Market
ADDRESSING UNDERSERVED NEEDS ASIAN-CENTRIC CANCERS, A US$40B MARKET5 Asians comprise 6% of clinical trial patients in For personal use only FDA approved drugs2 … yet 60% of the world is Asian UNDER-REPRESENTATION IN DRUG DEVELOPMENT MISMATCH WITH GLOBAL INCIDENCE Ethnic Breakdown of Clinical Trials
Slide 6: How Our Next-Gen PDT (Photosoft) Works
HOW OUR NEXT-GEN PDT (PHOTOSOFTTM) WORKS PROPRIETARY PHOTOSENSITIVE COMPOUNDS + LIGHT ACTIVATION Next-Gen Photodynamic Therapy (PDT): Drug activated by light that overcomes For personal use only significant shortcomings & side effects of approved PDT treatments 1. Delivery 2. Light Activation 3. Sel
Slide 7: Technology Highlights
TECHNOLOGY HIGHLIGHTS STRONG CLINICAL DATA AND PARTNERSHIPS, MULTIPLE TARGETS Key Advantages For personal use only • Platform technology scalable, multiple indications, 300+ patented compounds • Selectively targets multiple cancers and activates the immune system* • Theragnostic Potential: Violet li
Slide 8: Lead Cancer Drug Candidate INV043
LEAD CANCER DRUG CANDIDATE INV043 MULTIPLE CANCERS, ATTRACTIVE THERAPEUTIC PROFILE For personal use only Lead Cancer Drug Candidate: INV043 Effective in regressing multiple types of cancer in human trials and in vivo1 PhotosoftTM Potency: ~600x greater phototoxicity than Talaporfin (widely used phot
Slide 9: PoC Prostate Cancer Clinical Trial Results
PoC PROSTATE CANCER CLINICAL TRIAL RESULTS INVESTIGATOR-LED PROSTATE CANCER STUDY USING INV043* TREATMENT PROTOCOL SAFE AND WELL TOLERATED For personal use only ▪ 41 patients dosed (16 readouts, 25 limited data ▪ No serious adverse events and all adverse due to COVID lockdown limitations) events wer
Slide 10: Phase I/II Non-Melanoma Skin Cancer Trial
PHASE I/II NON-MELANOMA SKIN CANCER TRIAL PRELIMINARY PATIENT GROUP FINDINGS Change in Size of Lesions Safety Review Committee (SRC) Findings For personal use only Treated and untreated lesions* (initial patient group, n=12) ▪ No adverse events identified and no pain reported (vs. current PDT treatm
Slide 11: INV043 Fluoresces Cancers Under Violet Light
INV043 FLUORESCES CANCERS UNDER VIOLET LIGHT DIAGNOSTIC POTENTIAL Clearer surgical margins may increase precision in resecting cancer tissue For personal use only Patient 101-002 from Ph I/II NMSC Trial: Day 1 of the treatment Potential Diagnostic Applications: ▪ Identify residual cancers that are d
Slide 12: Theragnostic Potential of INV043
THERAGNOSTIC POTENTIAL OF INV043 ONE DRUG TO FIND AND TREAT MULTIPLE CANCERS SELECTIVE TARGETING PROTECTIVE IMMUNITY For personal use only Control Treated Photos show primary pancreatic (Human PANC1) cancer (Hudson Institute animal study). Small metastatic nodules on the liver visible to naked eye w
Slide 13: Combination with Immune Checkpoint Inhibitors
COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS (ICIs) IMPROVING IMMUNOTHERAPY OUTCOMES, PARTNERSHIP POTENTIAL PETER MAC: ~80% RESPONSE RATE vs. 12.5%1 ICI ONLY (ANAL SCC CANCER, TOPICAL, IN VIVO)3 Why This Matters For personal use only ▪ Attractive Market: World’s #1 best selling class of drugs – glo
Slide 14: Cancer: Target Indications and Timeframes
CANCER: TARGET INDICATIONS AND TIMEFRAMES MULTIPLE CLINICAL TRIALS AND INDICATIONS DISEASE AREA FUNDING SOURCE CY2025 CY2026 >CY2027 For personal use only CANCER (HUMAN) Follow up and monitoring Non-Melanoma Skin Cancers (Topical)1 Self-funded Adaptive study design Peter Mac Anogenital Cancers (Topi
Slide 15: Collaboration with Protect Animal Health
COLLABORATION WITH PROTECT ANIMAL HEALTH LUCRATIVE COMPANION ANIMAL MARKET OPPORTUNITY New Market Potential For personal use only • Reinforces Photosoft as a platform technology with multiple market opportunities • Invion has hundreds of proprietary PhotosoftTM compounds in Founded in 2019, listed i
Slide 16: Experienced Team
EXPERIENCED TEAM THE RIGHT EXPERTISE FOR SUCCESS PROF THIAN CHEW PROF ROBERT RAMSAY EXECUTIVE CHAIRMAN & CEO SCIENTIFIC ADVISOR For personal use only • Co-Founder, Chronic Airway Therapeutics • 30+ years research in cancer biology &translational medicine • Advisory Board, Stanford Medicine CARE • Se
Slide 17: Investor and Media Enquiries
For personal use only Sign up to receive regular updates, provide feedback and participate in discussions: https://investors.inviongroup.com/ For more information, go to www.inviongroup.com Investor and Media enquiries: Thian Chew (Chairman & CEO) Brendon Lau (Investor & Media Relations) T: +61 3 96